

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 78504

Title: Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04471126

Position: Peer Reviewer

Academic degree: DNB, MBBS, MD

Professional title: Professor

Reviewer's Country/Territory: India

Author's Country/Territory: China

Manuscript submission date: 2022-06-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-07-01 05:21

Reviewer performed review: 2022-07-15 01:15

Review time: 13 Days and 19 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The abstract is too short and non informative, kindly elaborate and shift the image provided in the abstract to the introduction segment of the main manuscript. The tables are good and well structured, however they must be referenced adequately, the results which are depicted in them must have been picked up from published literature and kindly add the reference number in tables too. Few references are incomplete for example number 7, 8, 14 page number is missing, kindly check all

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 78504

Title: Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05837295

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: India

Author's Country/Territory: China

Manuscript submission date: 2022-06-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-07-29 06:15

Reviewer performed review: 2022-07-29 06:22

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Nice article.this will definitely act as a game changer in breast cancer patients treatment.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 78504

Title: Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05387164

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-06-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-07-29 01:17

Reviewer performed review: 2022-07-29 22:16

Review time: 20 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Dear author Thank you for the submission of your article to our journal. I've just read your paper and felt some problems as follows; Major points 1. You should clarify what the reader should understand about ubiquitin-specific proteases and ubiquitin-specific protease inhibitors. 2. Abstract should state the main points of the paper. Minor points 1. You should correctly number the subheadings. 2. You should not full spell the word once expressed as an abbreviation such as ubiquitin specific peptidase (USP). 3. You made many careless and mistakes such as "could n promote" and " inhibit". 4. You made many strange expressions such as " leading to a variety of diseases, such as tumorigenesis" and ideal candidates as cancer targets for drug development ". 5. Table 1 should contain reference numbers.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 78504

Title: Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05387164

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-06-30

Reviewer chosen by: Ji-Hong Liu

Reviewer accepted review: 2022-08-31 06:53

Reviewer performed review: 2022-08-31 06:56

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Dear author Thank you for the submission of your article you our journal. I've just read your paper and felt some problems as follows; Major point You should clarify what the reader should understand about ubiquitin-specific proteases and ubiquitin-specific protease inhibitors especially in the abstract. Minor points P3 Line 3. The expression "diagnoses female cancers" is strange. Line 14-5 leading to a variety of diseases, such as tumorigenesis[4]. Tumorigenesis is not a disease. Line 17 play→plays Line 21. Promoted →promotes Line 23. abolished→abolish Line 30. participated→participate P5 Line 7. 3 USPs and breast cancer Why is the numbering is "3"? Line 21 3.2 USP4 Why is the numbering is "3.2"? Line 24. inhibite→inhibit Line 39 2. USP7 Why is the numbering is "2"? Line 32. member→a member Line 39. The expression "Association of USP7 with taxanes response " is strange. P6 Line 4 3.4 USP9X Why is the numbering is "3.4"? Line 18. "could n promote" ?? Line 27-8 Involving in the progression of breast cancer, USP14 promotes the proliferation and metastasis, but inhibiting apoptosis[52] This sentence is grammatically incorrect. P7 Line 16-7. The expression "exhibits aberrant an expression" is strange. Line 30 The expression "tumor-adjacent tissues" is strange. Line 39. was→were inhibit→inhibited P8 Line 1-2 The expression"USP51 was found to be a bona fide target of CDK4/6, CDK4/6-USP51-ZEB1 axis plays a key role in breast cancer metastasis" is strange. Line 8-9 The expression"the discovery of USP inhibitors reported mainly relied on high-throughput screening." Is strange. Line 11. two of them (b-AP15 and VLX1570) was→two of them (b-AP15 and VLX1570) were Line 32 suppressesing→suppressing Line 34 The expression"Only two USP2 inhibitors were



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

reported in breast cancer application.” is strange. Line 36 The expression”
BRCA1-deficient breast cancer cell lines are distinct sensitivities to 6-TG” is strange. P9
Line 3 supress→supresses Line 2 promising anticancer drugs→a promising anticancer
drug P11 Line 29